Treatment Detection and Movement Disorder Society-Unified Parkinson's Disease Rating Scale, Part III Estimation Using Finger Tapping Tasks
- PMID: 37401265
- DOI: 10.1002/mds.29520
Treatment Detection and Movement Disorder Society-Unified Parkinson's Disease Rating Scale, Part III Estimation Using Finger Tapping Tasks
Abstract
The validation of objective and easy-to-implement biomarkers that can monitor the effects of fast-acting drugs among Parkinson's disease (PD) patients would benefit antiparkinsonian drug development. We developed composite biomarkers to detect levodopa/carbidopa effects and to estimate PD symptom severity. For this development, we trained machine learning algorithms to select the optimal combination of finger tapping task features to predict treatment effects and disease severity. Data were collected during a placebo-controlled, crossover study with 20 PD patients. The alternate index and middle finger tapping (IMFT), alternative index finger tapping (IFT), and thumb-index finger tapping (TIFT) tasks and the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III were performed during treatment. We trained classification algorithms to select features consisting of the MDS-UPDRS III item scores; the individual IMFT, IFT, and TIFT; and all three tapping tasks collectively to classify treatment effects. Furthermore, we trained regression algorithms to estimate the MDS-UPDRS III total score using the tapping task features individually and collectively. The IFT composite biomarker had the best classification performance (83.50% accuracy, 93.95% precision) and outperformed the MDS-UPDRS III composite biomarker (75.75% accuracy, 73.93% precision). It also achieved the best performance when the MDS-UPDRS III total score was estimated (mean absolute error: 7.87, Pearson's correlation: 0.69). We demonstrated that the IFT composite biomarker outperformed the combined tapping tasks and the MDS-UPDRS III composite biomarkers in detecting treatment effects. This provides evidence for adopting the IFT composite biomarker for detecting antiparkinsonian treatment effect in clinical trials. © 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Keywords: Movement Disorder Society-Unified Parkinson's Disease Rating Scale; Parkinson's disease; classification; finger tapping; machine learning; regression.
© 2023 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Similar articles
-
A Placebo-Controlled Study to Assess the Sensitivity of Finger Tapping to Medication Effects in Parkinson's Disease.Mov Disord Clin Pract. 2022 Sep 27;9(8):1074-1084. doi: 10.1002/mdc3.13563. eCollection 2022 Nov. Mov Disord Clin Pract. 2022. PMID: 36339295 Free PMC article.
-
A low-cost vision system based on the analysis of motor features for recognition and severity rating of Parkinson's Disease.BMC Med Inform Decis Mak. 2019 Dec 12;19(Suppl 9):243. doi: 10.1186/s12911-019-0987-5. BMC Med Inform Decis Mak. 2019. PMID: 31830986 Free PMC article.
-
Correlation between the Movement Disorders Society Unified Parkinson's Disease rating scale (MDS-UPDRS) and the Unified Parkinson's Disease rating scale (UPDRS) during L-dopa acute challenge.Parkinsonism Relat Disord. 2011 Nov;17(9):705-7. doi: 10.1016/j.parkreldis.2011.07.002. Epub 2011 Jul 23. Parkinsonism Relat Disord. 2011. PMID: 21784692
-
Does levodopa slow or hasten the rate of progression of Parkinson's disease?J Neurol. 2005 Oct;252 Suppl 4:IV37-IV42. doi: 10.1007/s00415-005-4008-5. J Neurol. 2005. PMID: 16222436 Review.
-
Deep Learning for hand tracking in Parkinson's Disease video-based assessment: Current and future perspectives.Artif Intell Med. 2024 Aug;154:102914. doi: 10.1016/j.artmed.2024.102914. Epub 2024 Jun 17. Artif Intell Med. 2024. PMID: 38909431 Review.
Cited by
-
Evaluation of Free-Living Motor Symptoms in Patients With Parkinson Disease Through Smartwatches: Protocol for Defining Digital Biomarkers.JMIR Res Protoc. 2025 Jul 28;14:e72820. doi: 10.2196/72820. JMIR Res Protoc. 2025. PMID: 40720803 Free PMC article.
References
-
- Davie CA. A review of Parkinson's disease. Br Med Bull 2008;86(1):109-127. https://doi.org/10.1093/bmb/ldn013
-
- Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79(4):368-376. https://doi.org/10.1136/jnnp.2007.131045
-
- Regnault A, Boroojerdi B, Meunier J, Bani M, Morel T, Cano S. Does the MDS-UPDRS provide the precision to assess progression in early Parkinson's disease? Learnings from the Parkinson's progression marker initiative cohort. J Neurol 2019;266:1927-1936. https://doi.org/10.1007/s00415-019-09348-3
-
- Goetz CG et al. Movement Disorder Society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 2008;23(15):2129-2170. https://doi.org/10.1002/mds.22340
-
- Martinez-Martin P, Rodriguez-Blazquez C, Alvarez-Sanchez M, et al. Expanded and independent validation of the Movement Disorder Society-unified Parkinson's disease rating scale (MDS-UPDRS). J Neurol 2013;260(1):228-236. https://doi.org/10.1007/s00415-012-6624-1
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous